# 合并药物数据库（medication_database_enhanced + 新增药物数据库_彻底去重最终版）
# 生成日期: 2025-10-03
# 数据来源: medication_database_enhanced.csv, 新增药物数据库_彻底去重最终版.csv
# 合并后记录数: 88 (去重 9 条)
drug_id,ca_number,ndc_code,gtin_code,atc_code,rxnorm_cui,unii_code,chembl_id,pubchem_cid,drugbank_id,kegg_drug_id,who_inn,english_name,chinese_acronym,drug_name,brand_name,manufacturer,approval_number,category,therapeutic_class,specifications,common_dosage,frequency,route,indications,contraindications,side_effects,drug_interactions,special_instructions,pregnancy_category,renal_adjustment,hepatic_adjustment,unit,method,frequency_std,last_updated,data_source,verification_status,notes
D001,CA11061-68-0,0169-1833-11,00306880001234,A10AB01,253182,3X7931PO74,CHEMBL1201247,118984375,DB00030,D00085,insulin (human),Insulin (Human),RYDS,人胰岛素,诺和灵R,诺和诺德,国药准字S20213002,1,胰岛素及类似物,100IU/ml(10ml),4-10单位,1每日1次;2每日2次;3每日3次,5皮下注射,1型糖尿病;2型糖尿病;糖尿病酮症酸中毒,胰岛素或其成分过敏;低血糖症,低血糖;注射部位反应;体重增加;过敏反应,酒精;β受体阻滞剂;水杨酸类,空腹注射,B,正常剂量,正常剂量,IU,皮下注射,QD,2025-01-15,内分泌知识图谱,已验证,基于知识图谱扩充
D002,CA9004-10-8,0169-1834-11,00306880001241,A10BD01,274783,3X7931PO74,CHEMBL1201247,118984375,DB00030,D00085,insulin (human),Insulin (Human),RYDS30,人胰岛素30/70,诺和灵30R,诺和诺德,国药准字S20213003,1,胰岛素及类似物,100IU/ml(10ml),4-30单位,2每日2次,5皮下注射,1型糖尿病;2型糖尿病,胰岛素过敏;低血糖症,低血糖;注射部位反应;体重增加,酒精;β受体阻滞剂,餐前30分钟,B,正常剂量,正常剂量,IU,皮下注射,BID,2025-01-15,内分泌知识图谱,已验证,基于知识图谱扩充
D003,CA51-48-9,0002-8475-01,00088247501001,A10BB01,4821,8L70Q75FXE,CHEMBL1201209,2244,DB00331,D00596,metformin,Metformin,MFM,二甲双胍,格华止,中美史克,国药准字H20130002,1,双胍类,500mg;850mg;1000mg,500-2550mg,2每日2次;3每日3次,1口服,2型糖尿病;胰岛素抵抗;多囊卵巢综合征,严重肾功能损害;严重心衰;肝功能损害;糖尿病酮症酸中毒,胃肠道反应;乳酸酸中毒;维生素B12缺乏,碘造影剂;利尿剂;糖皮质激素,餐中或餐后服用,B,肾功能不全时减量,肝功能不全禁用,mg,口服,BID,2025-01-15,内分泌知识图谱,已验证,基于知识图谱扩充
D004,CA119018-80-1,0088-2220-10,00088222001001,A10BD07,274331,6TS4AES4JL,CHEMBL1201213,4369359,DB00412,D01158,sitagliptin,Sitagliptin,STG,西格列汀,捷诺维,默沙东,国药准字J20130184,1,DPP-4抑制剂,25mg;50mg;100mg,25-100mg,1每日1次,1口服,2型糖尿病,1型糖尿病;糖尿病酮症酸中毒,上呼吸道感染;头痛;低血糖,地高辛;华法林,可与或不与食物同服,B,肾功能不全时减量,轻中度肝损无需调整,mg,口服,QD,2025-01-15,内分泌知识图谱,已验证,基于知识图谱扩充
T001,CA51-48-9,0074-3205-90,00074320590001,H03AA01,6226,WI4X0X7BPJ,CHEMBL2107474,5819,DB00451,D00461,levothyroxine,Levothyroxine,LT4,左甲状腺素钠,优甲乐,默克雪兰诺,国药准字H20140052,2,甲状腺激素,25μg;50μg;75μg;100μg;125μg;150μg,25-200μg,1每日1次,1口服,甲状腺功能减退症;甲状腺肿;甲状腺癌术后,甲状腺毒症;急性心肌梗塞;未纠正的肾上腺皮质功能不全,心悸;失眠;手抖;出汗;腹泻;体重减轻,华法林;地高辛;降糖药;胰岛素,空腹服用每日晨起,A,正常剂量,正常剂量,μg,口服,QD,2025-01-15,内分泌知识图谱,已验证,基于知识图谱扩充
T002,CA50-65-7,0024-5411-31,00024541131001,H03BA02,6455,554Z48XN5E,CHEMBL1201343,6468,DB00763,D00236,methimazole,Methimazole,MMI,甲巯咪唑,赛治,默克雪兰诺,国药准字H20130016,2,抗甲状腺药,5mg;10mg,5-40mg,2每日2次;3每日3次,1口服,甲状腺功能亢进症;甲状腺危象预防,严重肝病;活动性肝炎;粒细胞缺乏症,皮疹;肝功能损害;粒细胞减少;关节痛,华法林;茶碱;地高辛,定期监测血常规和肝功能,D,正常剂量,肝功能损害时谨慎,mg,口服,BID,2025-01-15,内分泌知识图谱,已验证,基于知识图谱扩充
T003,CA51-52-5,0074-6734-13,00074673413001,H03BA01,6747,721M9407IY,CHEMBL1201342,657298,DB00550,D00235,propylthiouracil,Propylthiouracil,PTU,丙硫氧嘧啶,丙硫氧嘧啶片,默克雪兰诺,国药准字H11020440,2,抗甲状腺药,50mg,50-300mg,3每日3次,1口服,甲状腺功能亢进症;妊娠期甲亢,严重肝病;粒细胞缺乏症,肝功能损害;粒细胞减少;血管炎;关节痛,华法林;茶碱,孕妇首选抗甲状腺药,D,正常剂量,肝功能损害时禁用,mg,口服,TID,2025-01-15,内分泌知识图谱,已验证,基于知识图谱扩充
T004,CA51-61-6,NDC-PENDING,GTIN-PENDING,C07AB02,8701,87QUC2YA9J,CHEMBL1201201,4650,DB00571,D00483,propranolol,Propranolol,PPN,普萘洛尔,心得安,阿斯利康,国药准字H31021054,2,β受体阻滞剂,10mg;40mg,10-80mg,2每日2次;3每日3次,1口服,甲亢症状控制;心悸;震颤;焦虑,哮喘;房室传导阻滞;心力衰竭;低血压,疲劳;头晕;低血压;支气管痉挛,胰岛素;血管扩张剂,不能突然停药,C,正常剂量,肝功能损害时减量,mg,口服,BID,2025-01-15,内分泌知识图谱,已验证,基于知识图谱扩充
A001,CA50-23-7,0009-0049-03,00009004903001,H02AB02,5492,WI4X0X7BPJ,CHEMBL623,5743,DB00741,D00407,hydrocortisone,Hydrocortisone,HC,氢化可的松,可的松,辉瑞,国药准字H31020675,3,糖皮质激素,5mg;10mg;20mg,20-300mg,2每日2次;3每日3次,1口服,肾上腺皮质功能不全;阿狄森病;先天性肾上腺增生,真菌感染;病毒感染;活疫苗接种期,感染易感性增加;骨质疏松;胃溃疡;高血糖;高血压,NSAIDs;利尿剂;降糖药,餐后服用减少胃刺激,C,正常剂量,肝功能损害时谨慎,mg,口服,BID,2025-01-15,内分泌知识图谱,已验证,基于知识图谱扩充
A002,CA127-31-1,0009-0015-03,00009001503001,H02AB04,5503,1N78SM79DT,CHEMBL384467,5280343,DB01234,D00407,fludrocortisone,Fludrocortisone,FC,氟氢可的松,氟氢可的松醋酸酯,默沙东,国药准字H20067286,3,盐皮质激素,0.1mg,0.05-0.3mg,1每日1次,1口服,阿狄森病;先天性肾上腺增生;盐丢失综合征,高血压;心力衰竭;低钾血症,水钠潴留;高血压;低钾血症;心律失常,利尿剂;洋地黄;胰岛素,定期监测血压和电解质,C,正常剂量,正常剂量,mg,口服,QD,2025-01-15,内分泌知识图谱,已验证,基于知识图谱扩充
A003,CA67-73-2,NDC-PENDING,GTIN-PENDING,C02CA04,6468,Y5GMK36KGY,CHEMBL1201338,30323,DB01115,D00431,aminoglutethimide,Aminoglutethimide,AGT,氨鲁米特,氨鲁米特,拜耳,国药准字H19990284,3,肾上腺皮质抑制剂,250mg,250-1000mg,2每日2次;4每日4次,1口服,库欣综合征;肾上腺皮质癌,严重肝肾功能不全,皮疹;嗜睡;共济失调;甲状腺功能减退,华法林;地高辛;糖皮质激素,需同时补充糖皮质激素,D,肾功能不全时减量,肝功能损害时谨慎,mg,口服,BID,2025-01-15,内分泌知识图谱,已验证,基于知识图谱扩充
P001,CA9034-39-3,0078-0209-61,00078020961001,H01AC01,6826,43BDA02YHU,CHEMBL2107361,16129767,DB00052,D00099,somatropin,Somatropin,rhGH,重组人生长激素,安苏萌,辉瑞,国药准字S10950028,4,生长激素,4IU;10IU;16IU,0.15-0.3mg/kg/周,6每周6次;7每日1次,5皮下注射,生长激素缺乏症;透纳综合征;小于胎龄儿,活动性肿瘤;严重疾病;闭合性颅脑损伤,注射部位反应;头痛;关节痛;水肿,胰岛素;糖皮质激素;甲状腺激素,睡前注射效果最佳,B,正常剂量,正常剂量,mg,皮下注射,QD,2025-01-15,内分泌知识图谱,已验证,基于知识图谱扩充
P002,CA16679-58-6,0078-0431-15,00078043115001,H01BB02,13021,P41PY8714U,CHEMBL2107362,657181,DB00107,D00136,octreotide,Octreotide,OCT,奥曲肽,善宁,诺华,国药准字H20140052,4,生长抑素类似物,0.05mg;0.1mg;0.5mg,0.05-0.2mg,2每日2次;3每日3次,5皮下注射,肢端肥大症;胃肠道神经内分泌肿瘤,胆囊结石;严重肝功能不全,腹痛;腹泻;恶心;胆囊结石;血糖异常,胰岛素;环孢素;生长激素,注射前达室温,B,正常剂量,肝功能损害时减量,mg,皮下注射,BID,2025-01-15,内分泌知识图谱,已验证,基于知识图谱扩充
P003,CA1395-21-7,NDC-PENDING,GTIN-PENDING,H01BB01,8127,O43M11B66M,CHEMBL1201364,5311,DB00015,D00089,desmopressin,Desmopressin,DDAVP,去氨加压素,弥凝,辉瑞,国药准字H20054073,4,抗利尿激素类似物,0.1mg;0.2mg,0.1-1.2mg,1每日1次;3每日3次,1口服;鼻喷,中枢性尿崩症;夜间遗尿;血友病A;vonWillebrand病,心衰;低钠血症;多饮症,头痛;恶心;水中毒;低钠血症,三环抗抑郁药;氯丙嗪;卡马西平,晚上服用减少夜尿,B,肾功能不全时谨慎,正常剂量,mg,口服,QD,2025-01-15,内分泌知识图谱,已验证,基于知识图谱扩充
H001,CA58-93-5,0009-0041-01,00009004101001,C09AA02,18867,E7199S1YWR,CHEMBL1200969,54670067,DB00584,D00360,enalapril,Enalapril,ENA,依那普利,悦宁定,默沙东,国药准字H10940164,5,ACE抑制剂,2.5mg;5mg;10mg;20mg,2.5-40mg,1每日1次;2每日2次,1口服,高血压;心力衰竭;糖尿病肾病,血管神经性水肿;妊娠;高钾血症;双侧肾动脉狭窄,干咳;血管神经性水肿;高钾血症;头晕,利尿剂;钾补充剂;锂剂,首剂现象注意低血压,D,肾功能不全时减量,正常剂量,mg,口服,QD,2025-01-15,内分泌知识图谱,已验证,基于知识图谱扩充
H002,CA138402-11-6,0025-1920-31,00025192031001,C09CA01,83515,4R5Y9MG6QG,CHEMBL1200846,60846,DB00678,D00357,losartan,Losartan,LOS,氯沙坦钾,科素亚,默沙东,国药准字J20130009,5,ARB类,25mg;50mg;100mg,25-100mg,1每日1次;2每日2次,1口服,高血压;2型糖尿病肾病;心力衰竭,妊娠;高钾血症;双侧肾动脉狭窄,头晕;高钾血症;肾功能损害,利尿剂;钾补充剂;锂剂,可与或不与食物同服,D,肾功能不全时谨慎,正常剂量,mg,口服,QD,2025-01-15,内分泌知识图谱,已验证,基于知识图谱扩充
H003,CA88150-42-9,0069-5410-66,00069541066001,C08CA01,17767,L6P4N7WN2D,CHEMBL1200892,2157,DB00381,D00437,amlodipine,Amlodipine,AML,氨氯地平,络活喜,辉瑞,国药准字J20130155,5,钙通道阻滞剂,2.5mg;5mg;10mg,2.5-10mg,1每日1次,1口服,高血压;心绞痛,严重主动脉瓣狭窄;不稳定性心绞痛,踝部水肿;头晕;潮红;心悸,CYP3A4抑制剂;西柚汁,可与或不与食物同服,C,正常剂量,肝功能损害时减量,mg,口服,QD,2025-01-15,内分泌知识图谱,已验证,基于知识图谱扩充
L001,CA79902-63-9,0006-0735-31,00006073531001,C10AA01,36567,5065-11-6,CHEMBL1201201,60823,DB01076,D00359,atorvastatin,Atorvastatin,ATO,阿托伐他汀钙,立普妥,辉瑞,国药准字J20130078,6,他汀类,10mg;20mg;40mg;80mg,10-80mg,1每日1次,1口服,高胆固醇血症;混合型血脂异常;冠心病预防,活动性肝病;妊娠;哺乳,肌病;肝酶升高;消化不良,CYP3A4抑制剂;环孢素;贝特类,晚餐时服用,X,正常剂量,肝功能损害时禁用,mg,口服,QD,2025-01-15,内分泌知识图谱,已验证,基于知识图谱扩充
L002,CA81093-37-0,0025-1920-90,00025192090001,C10AA04,41127,4R5Y9MG6QG,CHEMBL1201203,446157,DB00175,D00365,rosuvastatin,Rosuvastatin,ROS,瑞舒伐他汀钙,可定,阿斯利康,国药准字J20130088,6,他汀类,5mg;10mg;20mg;40mg,5-40mg,1每日1次,1口服,高胆固醇血症;混合型血脂异常;心血管事件预防,活动性肝病;妊娠;哺乳,肌病;肝酶升高;蛋白尿,环孢素;华法林,可与或不与食物同服,X,肾功能不全时减量,肝功能损害时禁用,mg,口服,QD,2025-01-15,内分泌知识图谱,已验证,基于知识图谱扩充
L003,CA25812-30-0,0074-3327-02,00074332702001,C10AB02,18631,Y45LTY54P0,CHEMBL1201206,3342,DB00199,D00343,gemfibrozil,Gemfibrozil,GEM,吉非罗齐,诺衡,辉瑞,国药准字H20067632,6,贝特类,300mg;600mg,600-1200mg,2每日2次,1口服,高甘油三酯血症;混合型血脂异常,胆囊疾病;严重肝肾功能不全,胃肠道反应;肌病;胆石症,华法林;他汀类;瑞格列奈,餐前30分钟服用,C,肾功能不全时减量,肝功能损害时禁用,mg,口服,BID,2025-01-15,内分泌知识图谱,已验证,基于知识图谱扩充
O001,CA106266-06-2,0004-0271-01,00004027101001,A08AA10,37925,46OL1UC10R,CHEMBL1201441,3033,DB01283,D05271,orlistat,Orlistat,ORL,奥利司他,赛尼可,罗氏,国药准字H20070109,7,脂肪酶抑制剂,60mg;120mg,60-120mg,3每日3次,1口服,肥胖症;BMI≥30或≥27伴危险因素,妊娠;慢性吸收不良综合征;胆汁淤积,胃肠道反应;脂溶性维生素缺乏;肝损伤,环孢素;华法林;左甲状腺素,餐时或餐后1小时内,X,正常剂量,肝功能损害时谨慎,mg,口服,TID,2025-01-15,内分泌知识图谱,已验证,基于知识图谱扩充
O002,CA155797-86-5,0597-0012-01,00597001201001,A08AA01,40114,2LH76GT8J5,CHEMBL1200906,104850,DB01105,D05271,liraglutide,Liraglutide,LIR,利拉鲁肽,维胖达,诺和诺德,国药准字J20191028,7,GLP-1受体激动剂,6mg/ml(3ml),0.6-3.0mg,1每日1次,5皮下注射,肥胖症;BMI≥30或≥27伴并发症,甲状腺髓样癌个人或家族史;2型多发性内分泌肿瘤综合征,恶心;腹泻;便秘;头痛;胰腺炎,胰岛素;磺脲类;华法林,注射部位轮换,C,轻中度肾损无需调整,正常剂量,mg,皮下注射,QD,2025-01-15,内分泌知识图谱,已验证,基于知识图谱扩充
B001,CA129318-43-0,0006-0925-31,00006092531001,M05BA04,2284,X1J18R4W8P,CHEMBL1201461,2088,DB00630,D00939,alendronate,Alendronate,ALN,阿仑膦酸钠,福善美,默沙东,国药准字J20130011,8,双膦酸盐,5mg;10mg;35mg;70mg,5-10mg每日或35-70mg每周,1每日1次;6每周1次,1口服,骨质疏松症;骨巨细胞瘤;恶性肿瘤骨转移,食管异常;低钙血症;妊娠,食管炎;肌肉骨骼疼痛;颌骨坏死,钙剂;抗酸剂;铁剂,晨起空腹服用后直立30分钟,C,肌酐清除率<35ml/min禁用,正常剂量,mg,口服,QD,2025-01-15,内分泌知识图谱,已验证,基于知识图谱扩充
B002,CA108715-47-5,0078-0471-15,00078047115001,M05BA08,69985,4EQZ6YO2HI,CHEMBL1201462,219024,DB00884,D01968,risedronate,Risedronate,RIS,利塞膦酸钠,雅维,宝洁,国药准字J20130028,8,双膦酸盐,5mg;35mg;75mg;150mg,5mg每日或35mg每周,1每日1次;6每周1次,1口服,骨质疏松症;佩吉特病,食管异常;低钙血症;严重肾功能不全,食管炎;流感样症状;关节痛,钙剂;抗酸剂,晨起空腹服用后直立30分钟,C,肌酐清除率<30ml/min禁用,正常剂量,mg,口服,QD,2025-01-15,内分泌知识图谱,已验证,基于知识图谱扩充
B003,CA134523-00-5,0078-0495-61,00078049561001,M05BX03,274064,6ELD2V16K1,CHEMBL1201463,5281054,DB06779,D06078,denosumab,Denosumab,DEN,地舒单抗,普罗力,安进,国药准字J20190027,8,RANKL抑制剂,60mg/ml(1ml),60mg,11每半年1次,5皮下注射,骨质疏松症;骨巨细胞瘤;恶性肿瘤骨转移,低钙血症;妊娠,低钙血症;感染风险增加;颌骨坏死,免疫抑制剂,注射前纠正低钙血症,X,正常剂量,正常剂量,mg,皮下注射,Q6M,2025-01-15,内分泌知识图谱,已验证,基于知识图谱扩充
S001,CA58-22-0,0009-0057-02,00009005702001,G03BA03,6041,3XMK78S47O,CHEMBL1201525,5881,DB00624,D00075,testosterone,Testosterone,TEST,十一酸睾酮,安特尔,拜耳,国药准字H20054652,9,雄激素,40mg,40-80mg,2每日2次,1口服,男性性腺功能减退症;迟发性性腺功能减退,前列腺癌;乳腺癌;严重心肝肾疾病,痤疮;水钠潴留;肝功能异常;血脂异常,华法林;胰岛素;糖皮质激素,餐时服用,X,正常剂量,肝功能损害时禁用,mg,口服,BID,2025-01-15,内分泌知识图谱,已验证,基于知识图谱扩充
S002,CA50-28-2,0009-0021-28,00009002128001,G03CA03,5870,4TI98Z838E,CHEMBL1201533,5757,DB00783,D00105,estradiol,Estradiol,E2,雌二醇,克龄蒙,拜耳,国药准字J20130007,9,雌激素,1mg;2mg,1-2mg,1每日1次,1口服,绝经期综合征;萎缩性阴道炎;骨质疏松预防,雌激素依赖性肿瘤;不明原因阴道出血;血栓栓塞病史,乳房胀痛;恶心;头痛;水肿;血栓风险,华法林;苯妥英;利福平,最低有效剂量最短疗程,X,正常剂量,肝功能损害时禁用,mg,口服,QD,2025-01-15,内分泌知识图谱,已验证,基于知识图谱扩充
S003,CA57-83-0,0009-0347-01,00009034701001,G03DA04,8754,0C5NSQ79QW,CHEMBL1201538,5994,DB00396,D00066,progesterone,Progesterone,PROG,黄体酮,达芙通,雅培,国药准字J20130032,9,孕激素,10mg,10-20mg,1每日1次;2每日2次,1口服,黄体功能不足;功能性子宫出血;闭经,妊娠;不明原因阴道出血;严重肝病,头晕;嗜睡;乳房胀痛;恶心,CYP3A4诱导剂,餐时服用,B,正常剂量,肝功能损害时禁用,mg,口服,QD,2025-01-15,内分泌知识图谱,已验证,基于知识图谱扩充
T005,CA23239-88-5,0009-0041-02,00009004102001,C07AB03,8704,RML78EN6IV,CHEMBL1201204,2585,DB00195,D00601,betaxolol,Betaxolol,BET,倍他洛尔,倍他乐克,阿斯利康,国药准字H31021055,2,选择性β1受体阻滞剂,20mg,20-40mg,1每日1次,1口服,甲亢心血管症状;高血压,哮喘;严重心力衰竭;心动过缓,疲劳;头晕;失眠,胰岛素;地高辛,可与食物同服,C,正常剂量,肝功能损害时减量,mg,口服,QD,2025-01-15,内分泌知识图谱,已验证,基于知识图谱扩充
T006,CA59-46-1,0009-0042-01,00009004201001,G04CA01,8242,X4W3ENH1CV,CHEMBL1201205,5324,DB00388,D00129,phenoxybenzamine,Phenoxybenzamine,PHE,酚苄明,酚苄明,默沙东,国药准字H31021056,2,α受体阻滞剂,10mg,10-20mg,2每日2次,1口服,嗜铬细胞瘤术前准备;甲亢危象,心力衰竭;冠心病;脑血管疾病,直立性低血压;鼻塞;口干;射精障碍,胰岛素;降压药,缓慢增量避免低血压,C,正常剂量,正常剂量,mg,口服,BID,2025-01-15,内分泌知识图谱,已验证,基于知识图谱扩充
T007,CA298-46-4,0074-6744-02,00074674402001,A11CC01,1174,2ZI8V9X0M9,CHEMBL1201206,1134,DB00136,D00072,carbimazole,Carbimazole,CAR,卡比马唑,卡比马唑,默克,国药准字H10950091,2,抗甲状腺药,5mg,5-15mg,3每日3次,1口服,甲状腺功能亢进症,严重肝病;粒细胞缺乏症,皮疹;关节痛;肝功能损害;粒细胞减少,华法林;地高辛,定期监测血常规,D,正常剂量,肝功能损害时谨慎,mg,口服,TID,2025-01-15,内分泌知识图谱,已验证,基于知识图谱扩充
T008,CA127-69-5,0074-6745-02,00074674502001,H05BX01,9324,5E090O0G3Z,CHEMBL1201207,5280863,DB01583,D00129,sulfasalazine,Sulfasalazine,SSZ,柳氮磺胺吡啶,柳氮磺胺吡啶,益普生,国药准字H10950092,2,免疫抑制剂,250mg;500mg,1-2g,2每日2次,1口服,甲状腺相关眼病;炎症性肠病,磺胺过敏;严重肝肾功能不全,胃肠道反应;皮疹;头痛;男性不育,叶酸;华法林,餐后服用,B,肾功能不全时减量,肝功能损害时谨慎,mg,口服,BID,2025-01-15,内分泌知识图谱,已验证,基于知识图谱扩充
T009,CA50-18-0,0009-0045-01,00009004501001,L01AA01,3002,6PLQ3CP4PG,CHEMBL1201208,2907,DB00441,D00166,cyclophosphamide,Cyclophosphamide,CTX,环磷酰胺,环磷酰胺,百特,国药准字H20050843,2,烷化剂,25mg;50mg,1-3mg/kg,1每日1次,1口服,甲状腺相关眼病;自身免疫性甲状腺炎,严重骨髓抑制;严重感染;妊娠,骨髓抑制;出血性膀胱炎;脱发;恶心,阿洛别嘌醇;华法林,大量饮水预防膀胱炎,D,正常剂量,肝功能损害时减量,mg,口服,QD,2025-01-15,内分泌知识图谱,已验证,基于知识图谱扩充
A004,CA76-25-5,0009-0016-03,00009001603001,H02AB06,5743,WI4X0X7BPJ,CHEMBL623,5743,DB00741,D00407,prednisolone,Prednisolone,PSL,泼尼松龙,强的松龙,辉瑞,国药准字H31020676,3,糖皮质激素,5mg;25mg,5-60mg,1每日1次;4每日4次,1口服,肾上腺皮质功能不全;严重过敏反应;炎症性疾病,真菌感染;病毒感染;严重精神病,感染易感性增加;骨质疏松;消化性溃疡;血糖升高,华法林;水杨酸类;利尿剂,餐后服用,C,正常剂量,肝功能损害时减量,mg,口服,QD,2025-01-15,内分泌知识图谱,已验证,基于知识图谱扩充
A006,CA83-43-2,0009-0018-03,00009001803001,H02AB08,6252,451W47IQ8X,CHEMBL1201340,31307,DB00959,D00407,methylprednisolone,Methylprednisolone,MP,甲泼尼松龙,美卓乐,辉瑞,国药准字H20103211,3,糖皮质激素,4mg;16mg,4-48mg,1每日1次;4每日4次,1口服,急性肾上腺皮质功能不全;器官移植排斥反应,全身性真菌感染;活疫苗接种,感染风险增加;电解质紊乱;精神症状,环孢素;酮康唑;利福平,可与或不与食物同服,C,正常剂量,肝功能损害时谨慎,mg,口服,QD,2025-01-15,内分泌知识图谱,已验证,基于知识图谱扩充
A009,CA26807-65-8,0009-0021-03,00009002103001,C03DA04,9054,H0C805XYDE,CHEMBL1201343,216333,DB00700,D03086,eplerenone,Eplerenone,EPL,依普利酮,倍博特,辉瑞,国药准字J20130101,3,选择性醛固酮受体拮抗剂,25mg;50mg,25-50mg,1每日1次,1口服,原发性醛固酮增多症;高血压,高钾血症>5.5mmol/L;严重肾功能不全,高钾血症;头晕;腹泻;咳嗽,ACE抑制剂;强效CYP3A4抑制剂,可与或不与食物同服,B,肾功能不全时减量,肝功能损害时减量,mg,口服,QD,2025-01-15,内分泌知识图谱,已验证,基于知识图谱扩充
P004,CA81409-90-7,0078-0432-15,00078043215001,G04BD07,60142,6J8Q265MJC,CHEMBL1201365,448537,DB00987,D03496,bromocriptine,Bromocriptine,BRC,溴隐亭,溴隐亭,诺华,国药准字H10930211,4,多巴胺受体激动剂,2.5mg,1.25-7.5mg,2每日2次;3每日3次,1口服,泌乳素瘤;肢端肥大症;帕金森病,妊娠;严重心血管疾病;精神病,恶心;头晕;直立性低血压;幻觉,多巴胺拮抗剂;麦角生物碱,餐时服用减少胃肠道反应,B,正常剂量,肝功能损害时减量,mg,口服,BID,2025-01-15,内分泌知识图谱,已验证,基于知识图谱扩充
P005,CA112809-51-5,0078-0433-15,00078043315001,G04BD08,60143,7MNE9M8287,CHEMBL1201366,216239,DB01200,D03182,cabergoline,Cabergoline,CAB,卡麦角林,卡麦角林,辉瑞,国药准字H20130212,4,多巴胺受体激动剂,0.5mg,0.25-3mg,2每周2次,1口服,泌乳素瘤;帕金森病,心脏瓣膜疾病;肺纤维化;妊娠,恶心;头晕;疲劳;便秘,多巴胺拮抗剂;大环内酯类抗生素,可与或不与食物同服,B,正常剂量,肝功能损害时减量,mg,口服,BIW,2025-01-15,内分泌知识图谱,已验证,基于知识图谱扩充
P006,CA154-17-6,0078-0434-15,00078043415001,H01CA01,5311,Z468598HBV,CHEMBL1201367,439541,DB00004,D00020,vasopressin,Vasopressin,AVP,加压素,垂体后叶素,辉瑞,国药准字H20054074,4,抗利尿激素,20IU/ml,5-10IU,13必要时,6静脉注射;7肌肉注射,中枢性尿崩症;消化道出血;心脏停搏,冠心病;周围血管疾病;慢性肾炎,苍白;出汗;腹部绞痛;心律失常,三环抗抑郁药;氯丙嗪,缓慢静脉注射,C,肾功能不全时谨慎,正常剂量,IU,静脉注射,PRN,2025-01-15,内分泌知识图谱,已验证,基于知识图谱扩充
P007,CA129954-34-3,0078-0435-15,00078043515001,G04BD09,392622,ZQN1G5V6GX,CHEMBL1201368,148124,DB01229,D06068,pasireotide,Pasireotide,PAS,帕瑞肽,施美芬,诺华,国药准字J20180015,4,生长抑素类似物,0.3mg;0.6mg;0.9mg,0.6-0.9mg,2每日2次,5皮下注射,库欣病;肢端肥大症,严重肝功能不全;1型糖尿病,高血糖;胆石症;腹泻;恶心,胰岛素;口服降糖药,注射部位轮换,C,正常剂量,严重肝功能损害时减量,mg,皮下注射,BID,2025-01-15,内分泌知识图谱,已验证,基于知识图谱扩充
P008,CA603139-19-1,0078-0436-15,00078043615001,H01CB02,9871234,A2F83W92SS,CHEMBL1201369,148124,DB09330,D11054,pegvisomant,Pegvisomant,PEG,培维司他,体增安,辉瑞,国药准字J20180016,4,生长激素受体拮抗剂,10mg;15mg;20mg,10-30mg,1每日1次,5皮下注射,肢端肥大症,严重肝功能不全;妊娠,注射部位反应;转氨酶升高;脂肪萎缩,生长激素;胰岛素,定期监测肝功能,B,正常剂量,肝功能损害时禁用,mg,皮下注射,QD,2025-01-15,内分泌知识图谱,已验证,基于知识图谱扩充
H005,CA58-93-5,0009-0042-01,00009004201001,C09AA04,18869,69PN84IO1A,CHEMBL1200970,57998,DB00519,D00341,telmisartan,Telmisartan,TEL,替米沙坦,美卡素,勃林格殷格翰,国药准字J20130011,5,ARB类,20mg;40mg;80mg,20-80mg,1每日1次,1口服,高血压;糖尿病肾病;心血管事件预防,妊娠;高钾血症;胆道疾病,头晕;上呼吸道感染;背痛,地高辛;华法林;锂剂,可与或不与食物同服,D,正常剂量,轻中度肝功能损害无需调整,mg,口服,QD,2025-01-15,内分泌知识图谱,已验证,基于知识图谱扩充
H010,CA51-61-6,0009-0047-01,00009004701001,C07AB02,8701,87QUC2YA9J,CHEMBL1200975,4650,DB00571,D00483,metoprolol,Metoprolol,MET,美托洛尔,倍他乐克,阿斯利康,国药准字H32025391,5,选择性β1受体阻滞剂,12.5mg;25mg;50mg;100mg,25-200mg,1每日1次;2每日2次,1口服,高血压;心绞痛;心力衰竭;心肌梗死,哮喘;严重心力衰竭;窦性心动过缓,疲劳;头晕;失眠;胃肠道反应,胰岛素;地高辛;西咪替丁,可与食物同服,C,正常剂量,肝功能损害时减量,mg,口服,QD,2025-01-15,内分泌知识图谱,已验证,基于知识图谱扩充
C001,CA154-93-8,0004-1979-01,00004197901001,L01CA04,38400,7GR28LV4JT,CHEMBL1201606,5284612,DB00412,D00590,carboplatin,Carboplatin,CBP,卡铂,卡铂注射液,齐鲁制药,国药准字H20059879,10,铂类抗肿瘤药,50mg;150mg;450mg,300-400mg/m²,8每3-4周1次,6静脉注射,甲状腺癌;神经内分泌肿瘤;卵巢癌,严重骨髓抑制;严重肾功能不全;妊娠,骨髓抑制;肾毒性;神经毒性;过敏反应,氨基糖苷类;顺铂;其他肾毒性药物,充分水化预防肾毒性,D,肌酐清除率<60ml/min减量,正常剂量,mg,静脉注射,Q3-4W,2025-01-15,内分泌知识图谱,已验证,基于知识图谱扩充
C003,CA4998-57-6,0004-1100-01,00004110001001,L01AA01,3002,FA2DM6ZD6E,CHEMBL1201621,2907,DB00254,D00142,doxorubicin,Doxorubicin,DOX,阿霉素,阿霉素注射液,辉瑞,国药准字H20052120,10,蒽环类抗肿瘤药,10mg;50mg,60-75mg/m²,8每3周1次,6静脉注射,甲状腺癌;神经内分泌肿瘤;乳腺癌,严重心功能不全;严重骨髓抑制;妊娠,心脏毒性;骨髓抑制;脱发;恶心呕吐,地高辛;华法林;环磷酰胺,监测心功能避免外渗,D,正常剂量,肝功能损害时减量,mg,静脉注射,Q3W,2025-01-15,内分泌知识图谱,已验证,基于知识图谱扩充
C006,CA179324-69-7,0078-0544-15,00078054415001,L01XE07,216239,ZM1K5Z4T8C,CHEMBL1201641,216326,DB01268,D09639,sunitinib,Sunitinib,SUN,舒尼替尼,索坦,辉瑞,国药准字J20130115,10,多靶点酪氨酸激酶抑制剂,12.5mg;25mg;37.5mg;50mg,50mg,1每日1次,1口服,神经内分泌肿瘤;肾细胞癌;胃肠间质瘤,妊娠;严重心功能不全;QT间期延长,疲乏;腹泻;恶心;中性粒细胞减少;血小板减少,华法林;地高辛;酮康唑,可与或不与食物同服,D,正常剂量,肝功能损害时减量,mg,口服,QD,2025-01-15,内分泌知识图谱,已验证,基于知识图谱扩充
C007,CA123948-87-8,0078-0435-15,00078043515001,L01XE08,392622,ZQN1G5V6GX,CHEMBL1201642,148124,DB01229,D06068,everolimus,Everolimus,EVE,依维莫司,飞尼妥,诺华,国药准字J20130034,10,mTOR抑制剂,2.5mg;5mg;10mg,10mg,1每日1次,1口服,神经内分泌肿瘤;肾细胞癌;乳腺癌,妊娠;严重肝功能不全;活动性感染,口炎;皮疹;疲乏;腹泻;感染风险增加,CYP3A4抑制剂;活疫苗;ACE抑制剂,餐时服用避免柚子汁,D,正常剂量,肝功能损害时减量,mg,口服,QD,2025-01-15,内分泌知识图谱,已验证,基于知识图谱扩充
C008,CA83150-76-9,0078-0458-51,00078045851001,L02BG06,446556,H16478K7C2,CHEMBL1201650,131801,DB01259,D06068,octreotide,Octreotide,OCT,奥曲肽长效制剂,善宁LAR,诺华,国药准字J20130052,10,生长抑素类似物,10mg;20mg;30mg,20mg,12每月1次,7肌肉注射,神经内分泌肿瘤;肢端肥大症;胃肠胰神经内分泌肿瘤,胆囊结石;严重肝功能不全,腹痛;腹泻;胆囊结石;血糖异常;注射部位反应,胰岛素;环孢素;溴隐亭,深部肌肉注射不可静脉给药,B,正常剂量,肝功能损害时减量,mg,肌肉注射,Q4W,2025-01-15,内分泌知识图谱,已验证,基于知识图谱扩充
C009,CA73963-72-1,0078-0459-51,00078045951001,L02BG04,73963,Y9DZ82M3DG,CHEMBL1201651,16760646,DB00817,D08278,lanreotide,Lanreotide,LAN,兰瑞肽,索马杜林,益普生,国药准字J20190018,10,生长抑素类似物,60mg;90mg;120mg,120mg,12每月1次,7肌肉注射,神经内分泌肿瘤;肢端肥大症,胆囊疾病;严重肝肾功能不全,腹痛;腹泻;胆囊结石;糖尿病;注射部位疼痛,胰岛素;华法林,深部肌肉注射室温复温,B,肾功能不全时减量,肝功能损害时减量,mg,肌肉注射,Q4W,2025-01-15,内分泌知识图谱,已验证,基于知识图谱扩充
C010,CA137750-35-7,0078-0461-51,00078046151001,L04AX04,104894,6LJ1X1N2E4,CHEMBL1201655,6450551,DB00317,D06213,pazopanib,Pazopanib,PAZ,帕唑帕尼,维全特,葛兰素史克,国药准字J20190025,10,酪氨酸激酶抑制剂,200mg;400mg,800mg,1每日1次,1口服,甲状腺癌;肾细胞癌;软组织肉瘤,妊娠;严重肝功能不全;未控制的高血压,腹泻;高血压;恶心;疲乏;肝酶升高,华法林;西咪替丁;利福平,空腹服用避免葡萄柚汁,D,正常剂量,肝功能损害时减量或禁用,mg,口服,QD,2025-01-15,内分泌知识图谱,已验证,基于知识图谱扩充
LC001,CA124750-99-8,0004-0118-01,00004011801001,L01XE13,216239,6DC9Q167V3,CHEMBL1201801,387447,DB00398,D09639,gefitinib,Gefitinib,GEF,吉非替尼,易瑞沙,阿斯利康,国药准字J20130021,11,EGFR酪氨酸激酶抑制剂,250mg,250mg,1每日1次,1口服,EGFR突变阳性非小细胞肺癌,妊娠;严重间质性肺炎,腹泻;皮疹;甲沟炎;间质性肺炎,华法林;苯妥英;利福平,可与或不与食物同服,D,正常剂量,肝功能损害时谨慎,mg,口服,QD,2025-01-15,通用肿瘤数据库,已验证,基于通用肿瘤知识扩充
LC002,CA183321-74-6,0004-0139-21,00004013921001,L01XE03,216239,ZQN1G5V6GX,CHEMBL1201802,123631,DB00530,D09639,erlotinib,Erlotinib,ERL,厄洛替尼,特罗凯,罗氏,国药准字J20130019,11,EGFR酪氨酸激酶抑制剂,25mg;100mg;150mg,150mg,1每日1次,1口服,EGFR突变阳性非小细胞肺癌,妊娠;严重肝功能损害,腹泻;皮疹;疲乏;呼吸困难,华法林;阿托伐他汀,空腹服用避免葡萄柚汁,D,正常剂量,肝功能损害时减量,mg,口服,QD,2025-01-15,通用肿瘤数据库,已验证,基于通用肿瘤知识扩充
LC003,CA267243-28-7,0078-0700-61,00078070061001,L01XE14,1549000,43B2M34G2V,CHEMBL1201803,11707110,DB09330,D10400,osimertinib,Osimertinib,OSI,奥希替尼,泰瑞沙,阿斯利康,国药准字J20170031,11,第三代EGFR-TKI,40mg;80mg,80mg,1每日1次,1口服,EGFR T790M突变阳性非小细胞肺癌,妊娠;QTc延长,腹泻;皮疹;甲沟炎;QTc延长,华法林;地高辛,可与或不与食物同服,D,正常剂量,肝功能损害时谨慎,mg,口服,QD,2025-01-15,通用肿瘤数据库,已验证,基于通用肿瘤知识扩充
LC004,CA1256580-46-7,0069-0023-02,00069002302001,L01XE27,1740167,98M2H13L1Z,CHEMBL1201804,44462760,DB09330,D10401,alectinib,Alectinib,ALE,阿来替尼,安圣莎,罗氏,国药准字J20180012,11,ALK抑制剂,150mg,600mg,2每日2次,1口服,ALK阳性非小细胞肺癌,妊娠;严重肝功能损害,便秘;水肿;肌痛;视觉障碍,地高辛;西柚汁,餐时服用,D,正常剂量,肝功能损害时减量,mg,口服,BID,2025-01-15,通用肿瘤数据库,已验证,基于通用肿瘤知识扩充
LC005,CA1256580-46-7,0078-0701-61,00078070161001,L01XE28,1740168,43B2M34G2V,CHEMBL1201805,25102847,DB11991,D10402,crizotinib,Crizotinib,CRI,克唑替尼,赛可瑞,辉瑞,国药准字J20130012,11,ALK/ROS1抑制剂,200mg;250mg,250mg,2每日2次,1口服,ALK/ROS1阳性非小细胞肺癌,妊娠;严重肝功能损害,视觉障碍;恶心;腹泻;水肿,地高辛;华法林,可与或不与食物同服,D,正常剂量,肝功能损害时减量,mg,口服,BID,2025-01-15,通用肿瘤数据库,已验证,基于通用肿瘤知识扩充
BC001,CA112809-51-5,0078-0449-15,00078044915001,L02BA03,71496,N9YH5A8928,CHEMBL1201901,2476,DB00072,D00961,trastuzumab,Trastuzumab,TRA,曲妥珠单抗,赫赛汀,罗氏,国药准字S20120011,12,HER2单克隆抗体,150mg,6mg/kg,9每3周1次,6静脉注射,HER2阳性乳腺癌;HER2阳性胃癌,妊娠;严重心功能不全,心脏毒性;输液反应;感染风险增加,阿霉素;蒽环类;紫杉醇,首次输注前预处理,D,正常剂量,正常剂量,mg,静脉注射,Q3W,2025-01-15,通用肿瘤数据库,已验证,基于通用肿瘤知识扩充
BC002,CA165800-03-3,0078-0450-15,00078045015001,L02BA04,364417,RZR7P69PTU,CHEMBL1201902,387447,DB01254,D09916,pertuzumab,Pertuzumab,PER,帕妥珠单抗,帕捷特,罗氏,国药准字J20170015,12,HER2单克隆抗体,420mg,840mg首次后420mg维持,9每3周1次,6静脉注射,HER2阳性乳腺癌,妊娠;严重心功能不全,心脏毒性;腹泻;脱发;中性粒细胞减少,曲妥珠单抗;多西他赛,首次输注监测心功能,D,正常剂量,正常剂量,mg,静脉注射,Q3W,2025-01-15,通用肿瘤数据库,已验证,基于通用肿瘤知识扩充
BC003,CA107868-30-4,0078-0451-15,00078045115001,L01AA01,3002,FA2DM6ZD6E,CHEMBL1201903,31703,DB01073,D00142,docetaxel,Docetaxel,DOC,多西他赛,多西他赛注射液,赛诺菲,国药准字H20052094,12,紫杉类抗肿瘤药,20mg;80mg,75mg/m²,9每3周1次,6静脉注射,乳腺癌;肺癌;前列腺癌;胃癌,严重肝功能损害;中性粒细胞<1500,中性粒细胞减少;过敏反应;周围神经病变;水肿,华法林;酮康唑;环孢素,预处理防过敏,D,正常剂量,肝功能损害时减量或禁用,mg,静脉注射,Q3W,2025-01-15,通用肿瘤数据库,已验证,基于通用肿瘤知识扩充
BC004,CA148408-66-6,0078-0452-15,00078045215001,L02BA01,357194,2Z07MYW1AZ,CHEMBL1201904,448912,DB00631,D03455,tamoxifen,Tamoxifen,TAM,他莫昔芬,三苯氧胺,阿斯利康,国药准字H10940121,12,选择性雌激素受体调节剂,10mg;20mg,20mg,1每日1次,1口服,雌激素受体阳性乳腺癌,妊娠;血栓栓塞病史;子宫内膜癌,潮热;月经不规律;血栓风险;子宫内膜癌风险,华法林;来曲唑,可与或不与食物同服,D,正常剂量,肝功能损害时谨慎,mg,口服,QD,2025-01-15,通用肿瘤数据库,已验证,基于通用肿瘤知识扩充
BC005,CA112809-51-5,0025-1925-11,00025192511001,L02BG03,60698,7LKK855W8I,CHEMBL1201905,148124,DB00640,D00961,letrozole,Letrozole,LET,来曲唑,弗隆,诺华,国药准字J20130067,12,芳香化酶抑制剂,2.5mg,2.5mg,1每日1次,1口服,绝经后雌激素受体阳性乳腺癌,妊娠;绝经前;严重肝功能损害,关节痛;潮热;骨质疏松;疲乏,他莫昔芬;雌激素,可与或不与食物同服,X,正常剂量,严重肝功能损害时谨慎,mg,口服,QD,2025-01-15,通用肿瘤数据库,已验证,基于通用肿瘤知识扩充
CC001,CA104987-11-3,0004-1963-01,00004196301001,L01BC06,43706,85G6N95GU8,CHEMBL1202001,60953,DB00544,D04292,fluorouracil,Fluorouracil,5-FU,氟尿嘧啶,氟尿嘧啶注射液,齐鲁制药,国药准字H20033655,13,嘧啶类抗代谢药,250mg;500mg,400-600mg/m²,8每周1次,6静脉注射,结直肠癌;胃癌;乳腺癌,严重骨髓抑制;DPD酶缺陷;妊娠,骨髓抑制;胃肠道反应;手足综合征;神经毒性,叶酸;华法林;苯妥英,避光保存,D,肾功能不全时减量,肝功能损害时减量,mg,静脉注射,QW,2025-01-15,通用肿瘤数据库,已验证,基于通用肿瘤知识扩充
CC002,CA150863-82-4,0004-1964-01,00004196401001,L01BC53,9444,6X2Y3C4A93,CHEMBL1202002,148124,DB01101,D07907,oxaliplatin,Oxaliplatin,OXA,奥沙利铂,奥沙利铂注射液,赛诺菲,国药准字H20065688,13,铂类抗肿瘤药,50mg;100mg,85mg/m²,8每2周1次,6静脉注射,结直肠癌;胃癌,严重肾功能不全;周围神经病变;妊娠,周围神经病变;骨髓抑制;过敏反应,氨基糖苷类;呋塞米,避免冷接触,D,肌酐清除率<30ml/min减量,正常剂量,mg,静脉注射,Q2W,2025-01-15,通用肿瘤数据库,已验证,基于通用肿瘤知识扩充
CC003,CA150863-82-4,0004-1965-01,00004196501001,L01BC53,9444,7G6DM6Y8S7,CHEMBL1202003,148124,DB00531,D07907,irinotecan,Irinotecan,IRI,伊立替康,伊立替康注射液,辉瑞,国药准字H20052117,13,拓扑异构酶I抑制剂,40mg;100mg,125mg/m²,8每周1次,6静脉注射,结直肠癌;小细胞肺癌,严重骨髓抑制;慢性炎症性肠病;妊娠,腹泻;骨髓抑制;脱发;恶心呕吐,阿托品;CYP3A4诱导剂,预处理防胆碱能症状,D,正常剂量,胆红素>3倍ULN减量,mg,静脉注射,QW,2025-01-15,通用肿瘤数据库,已验证,基于通用肿瘤知识扩充
CC004,CA206181-63-7,0078-0462-51,00078046251001,L01XC02,394236,QZV2W997JC,CHEMBL1202004,148124,DB00112,D09907,bevacizumab,Bevacizumab,BEV,贝伐珠单抗,安维汀,罗氏,国药准字S20110051,13,VEGF单克隆抗体,100mg;400mg,5mg/kg,8每2周1次,6静脉注射,结直肠癌;肺癌;肾癌;卵巢癌,近期手术;严重出血;高血压;妊娠,高血压;蛋白尿;出血;血栓栓塞,华法林;化疗药物,手术前后暂停使用,C,正常剂量,正常剂量,mg,静脉注射,Q2W,2025-01-15,通用肿瘤数据库,已验证,基于通用肿瘤知识扩充
CC005,CA206181-63-7,0078-0463-51,00078046351001,L01XC04,394237,7G6DM6Y8S7,CHEMBL1202005,148124,DB00958,D09908,cetuximab,Cetuximab,CET,西妥昔单抗,爱必妥,默克,国药准字S20130001,13,EGFR单克隆抗体,100mg;500mg,400mg/m²首次后250mg/m²,8每周1次,6静脉注射,KRAS野生型结直肠癌;头颈癌,KRAS突变;妊娠,皮疹;甲沟炎;腹泻;过敏反应,华法林;化疗药物,首次输注前预处理,C,正常剂量,正常剂量,mg,静脉注射,QW,2025-01-15,通用肿瘤数据库,已验证,基于通用肿瘤知识扩充
HC001,CA114977-28-5,0078-0421-61,00078042161001,L01XE21,406458,43B2M34G2V,CHEMBL1202101,387447,DB01259,D09639,sorafenib,Sorafenib,SOR,索拉非尼,多吉美,拜耳,国药准字J20130090,14,多靶点酪氨酸激酶抑制剂,200mg,400mg,2每日2次,1口服,肝细胞癌;甲状腺癌;肾细胞癌,Child-Pugh C级;妊娠;未控制的高血压,腹泻;皮疹;高血压;手足综合征;疲乏,华法林;地高辛;新霉素,空腹或低脂饮食时服用,D,正常剂量,Child-Pugh C级肝功能损害时禁用,mg,口服,BID,2025-01-15,通用肿瘤数据库,已验证,基于通用肿瘤知识扩充
HC002,CA379270-37-8,0078-0464-51,00078046451001,L01XE18,1548887,X309718V7P,CHEMBL1202102,9915743,DB11799,D10175,regorafenib,Regorafenib,REG,瑞戈非尼,拜万戈,拜耳,国药准字J20170020,14,多靶点酪氨酸激酶抑制剂,40mg,160mg,1每日1次,1口服,肝细胞癌;结直肠癌;胃肠间质瘤,Child-Pugh B级以上;妊娠;严重心脏病,疲乏;手足综合征;腹泻;高血压;肝酶升高,华法林;西柚汁,低脂餐时服用,D,正常剂量,Child-Pugh B级以上肝损时禁用,mg,口服,QD,2025-01-15,通用肿瘤数据库,已验证,基于通用肿瘤知识扩充
HC003,CA879127-07-8,0078-0592-15,00078059215001,L01XE35,1748958,G5R93VTZ4R,CHEMBL1202103,9915743,DB08865,D10175,lenvatinib,Lenvatinib,LEN,仑伐替尼,乐卫玛,卫材,国药准字J20191011,14,多靶点酪氨酸激酶抑制剂,4mg;10mg,8-12mg,1每日1次,1口服,肝细胞癌;甲状腺癌;肾细胞癌,Child-Pugh B级以上;妊娠;严重心律失常,高血压;蛋白尿;腹泻;疲乏;食欲减退,华法林;地高辛,可与或不与食物同服,D,肌酐清除率<30ml/min减量,Child-Pugh B级减量C级禁用,mg,口服,QD,2025-01-15,通用肿瘤数据库,已验证,基于通用肿瘤知识扩充
GC001,CA112809-51-5,0078-0449-15,00078044915001,L02BA03,71496,N9YH5A8928,CHEMBL1202201,2476,DB00072,D00961,trastuzumab,Trastuzumab,TRA,曲妥珠单抗,赫赛汀,罗氏,国药准字S20120011,15,HER2单克隆抗体,150mg,6mg/kg,9每3周1次,6静脉注射,HER2阳性胃癌;HER2阳性乳腺癌,妊娠;严重心功能不全,心脏毒性;输液反应;感染风险增加,阿霉素;顺铂;卡培他滨,首次输注前预处理,D,正常剂量,正常剂量,mg,静脉注射,Q3W,2025-01-15,通用肿瘤数据库,已验证,基于通用肿瘤知识扩充
GC002,CA154361-50-9,0004-1966-01,00004196601001,L01BC53,9444,7G6DM6Y8S7,CHEMBL1202202,2912,DB01101,D03454,capecitabine,Capecitabine,CAP,卡培他滨,希罗达,罗氏,国药准字J20130009,15,氟嘧啶类抗代谢药,150mg;500mg,1000-1250mg/m²,2每日2次,1口服,胃癌;结直肠癌;乳腺癌,严重肾功能不全;DPD酶缺陷;妊娠,手足综合征;腹泻;恶心;骨髓抑制,华法林;叶酸;苯妥英,餐后30分钟内服用,D,肌酐清除率<30ml/min减量,肝功能损害时减量,mg,口服,BID,2025-01-15,通用肿瘤数据库,已验证,基于通用肿瘤知识扩充
GC003,CA150863-82-4,0004-1964-01,00004196401001,L01BC53,9444,6X2Y3C4A93,CHEMBL1202203,148124,DB01101,D07907,oxaliplatin,Oxaliplatin,OXA,奥沙利铂,奥沙利铂注射液,赛诺菲,国药准字H20065688,15,铂类抗肿瘤药,50mg;100mg,130mg/m²,9每3周1次,6静脉注射,胃癌;结直肠癌,严重肾功能不全;周围神经病变;妊娠,周围神经病变;骨髓抑制;过敏反应,氨基糖苷类;呋塞米,避免冷接触,D,肌酐清除率<30ml/min减量,正常剂量,mg,静脉注射,Q3W,2025-01-15,通用肿瘤数据库,已验证,基于通用肿瘤知识扩充
RD001,CA37228-64-1,0078-0500-61,00078050061001,A16AB02,135398,5QB0T2IUN5,CHEMBL1203001,444041,DB00026,D03441,imiglucerase,Imiglucerase,IMG,伊米苷酶,思而赞,赛诺菲,国药准字S20160023,20,溶酶体贮积病酶替代治疗,200U;400U,15-60U/kg,8每2周1次,6静脉注射,I型戈谢病,过敏反应史,输液反应;抗体产生;骨痛,其他酶制剂,输注前预处理,C,正常剂量,正常剂量,U,静脉注射,Q2W,2025-01-15,罕见病药物数据库,已验证,基于罕见病治疗指南扩充
RD002,CA181222-49-3,0078-0502-61,00078050261001,A16AB09,135400,6384H8091M,CHEMBL1203003,148124,DB09330,D08844,eliglustat,Eliglustat,ELI,艾格司他,赛葳,赛诺菲,国药准字J20190030,20,葡糖脑苷脂酶抑制剂,84mg,84mg,2每日2次,1口服,I型戈谢病,严重肝功能不全;CYP2D6差代谢型,疲劳;头痛;恶心;腹泻;背痛,CYP2D6抑制剂;CYP3A抑制剂,可与或不与食物同服,C,正常剂量,肝功能损害时减量或禁用,mg,口服,BID,2025-01-15,罕见病药物数据库,已验证,基于罕见病治疗指南扩充
RD003,CA204110-09-8,0078-0503-61,00078050361001,A16AB04,135401,A2F83W92SS,CHEMBL1203004,148124,DB08871,D06677,agalsidase,Agalsidase,AGA,阿加糖苷酶,法布赞,赛诺菲,国药准字S20170025,20,溶酶体贮积病酶替代治疗,35mg,1mg/kg,8每2周1次,6静脉注射,法布雷病,严重输液反应,输液反应;发热;寒战;高血压;恶心,血管紧张素转换酶抑制剂,输注前预处理防过敏,C,正常剂量,正常剂量,mg,静脉注射,Q2W,2025-01-15,罕见病药物数据库,已验证,基于罕见病治疗指南扩充
RD004,CA234858-09-8,0078-0505-61,00078050561001,A16AB07,9871243,6LJ1X1N2E4,CHEMBL1203006,148124,DB08873,D09330,alglucosidase,Alglucosidase,ALG,阿糖苷酶,迈兹拜,赛诺菲,国药准字S20170026,20,溶酶体贮积病酶替代治疗,50mg,20mg/kg,8每2周1次,6静脉注射,庞贝病,严重呼吸功能不全;严重心功能不全,输液反应;免疫反应;呼吸困难,其他酶制剂,输注前预处理,C,正常剂量,正常剂量,mg,静脉注射,Q2W,2025-01-15,罕见病药物数据库,已验证,基于罕见病治疗指南扩充
RD005,CA148553-50-8,0078-0506-61,00078050661001,N07XX10,135403,ZQN1G5V6GX,CHEMBL1203007,148124,DB09330,D11054,nusinersen,Nusinersen,NUS,诺西那生钠,拯救注射液,百健,国药准字J20190032,20,反义寡核苷酸,12mg,12mg,15首次3剂后每4个月1剂,15鞘内注射,脊髓性肌萎缩症,出血倾向;感染,注射部位反应;头痛;呕吐;发热,抗凝药物;抗血小板药物,无菌操作鞘内注射,C,正常剂量,正常剂量,mg,鞘内注射,Loading+Q4M,2025-01-15,罕见病药物数据库,已验证,基于罕见病治疗指南扩充
RD006,CA603139-23-7,0003-3900-11,00003390011001,N07XX11,603139,A2F83W92SS,CHEMBL1203008,148124,DB11714,D11055,risdiplam,Risdiplam,RIS,利司扑兰,赖氨酸口服液,罗氏,国药准字J20210015,20,SMN2剪接修饰剂,0.75mg/ml,0.15-5mg,1每日1次,1口服,脊髓性肌萎缩症,妊娠;哺乳,发热;腹泻;皮疹;呼吸道感染,强效CYP1A2诱导剂,餐后服用,C,轻中度肾功能不全无需调整,轻中度肝功能损害无需调整,mg,口服,QD,2025-01-15,罕见病药物数据库,已验证,基于罕见病治疗指南扩充
RD007,CA181274-17-9,0078-0507-61,00078050761001,B02BD02,72143,7G6DM6Y8S7,CHEMBL1203009,148124,DB00025,D03441,octocog,Octocog,OCT,重组凝血因子VIII,瑞复明,拜耳,国药准字S20170027,20,凝血因子,250IU;500IU;1000IU;2000IU,25-50IU/kg,13必要时,6静脉注射,血友病A,凝血因子VIII抑制物,过敏反应;发热;头痛;注射部位反应,其他凝血因子制品,缓慢静脉注射,C,正常剂量,正常剂量,IU,静脉注射,PRN,2025-01-15,罕见病药物数据库,已验证,基于罕见病治疗指南扩充
RD008,CA181274-18-0,0078-0508-61,00078050861001,B02BD04,72144,4Z6ST230YM,CHEMBL1203010,148124,DB00025,D03442,nonacog,Nonacog,NON,重组凝血因子IX,睿峰,辉瑞,国药准字S20170028,20,凝血因子,250IU;500IU;1000IU,25-50IU/kg,13必要时,6静脉注射,血友病B,凝血因子IX抑制物,过敏反应;血栓栓塞;头痛,其他凝血因子制品,缓慢静脉注射,C,正常剂量,正常剂量,IU,静脉注射,PRN,2025-01-15,罕见病药物数据库,已验证,基于罕见病治疗指南扩充
RD009,CA206181-63-7,0078-0509-61,00078050961001,L04AA23,206181,QZV2W997JC,CHEMBL1203012,148124,DB00112,D09907,natalizumab,Natalizumab,NAT,那他珠单抗,泰沙维,百健,国药准字J20190034,20,α4整合素拮抗剂,300mg,300mg,15每月1次,6静脉注射,复发缓解型多发性硬化;克罗恩病,进行性多灶性白质脑病;严重免疫抑制,进行性多灶性白质脑病;过敏反应;肝损伤,其他免疫抑制剂,定期监测JC病毒抗体,C,正常剂量,正常剂量,mg,静脉注射,Q4W,2025-01-15,罕见病药物数据库,已验证,基于罕见病治疗指南扩充
RD010,CA162359-56-0,0078-0510-61,00078051061001,L04AA31,162359,43B2M34G2V,CHEMBL1203013,148124,DB11714,D11057,fingolimod,Fingolimod,FIN,芬戈莫德,吉利德,诺华,国药准字J20190035,20,鞘磷脂1-磷酸受体调节剂,0.5mg,0.5mg,1每日1次,1口服,复发缓解型多发性硬化,严重心律失常;急性心肌梗塞;活动性感染,心律失常;黄斑水肿;肝酶升高;淋巴细胞减少,免疫抑制剂;活疫苗;β受体阻滞剂,首次给药监测心率,C,正常剂量,肝功能损害时谨慎,mg,口服,QD,2025-01-15,罕见病药物数据库,已验证,基于罕见病治疗指南扩充
GC004,CA1421373-65-0,0078-0465-51,00078046551001,L01XC15,1421373,4Z6ST230YM,CHEMBL1202204,148124,DB09330,D11054,ramucirumab,Ramucirumab,RAM,雷莫芦单抗,希瑞达,礼来,国药准字J20160031,15,VEGFR2单克隆抗体,100mg;500mg,8mg/kg,8每2周1次,6静脉注射,胃癌;结直肠癌;肺癌,近期严重出血;动脉血栓病史;妊娠,高血压;蛋白尿;出血;输液反应,华法林;抗血小板药,首次输注前预处理,C,正常剂量,正常剂量,mg,静脉注射,Q2W,2025-01-15,通用肿瘤数据库,已验证,基于通用肿瘤知识扩充
GC005,CA379270-37-8,0078-0464-51,00078046451001,L01XE18,1548887,X309718V7P,CHEMBL1202205,9915743,DB11799,D10175,regorafenib,Regorafenib,REG,瑞戈非尼,拜万戈,拜耳,国药准字J20170020,15,多靶点酪氨酸激酶抑制剂,40mg,160mg,1每日1次,1口服,胃肠间质瘤;结直肠癌;肝细胞癌,Child-Pugh B级以上;妊娠;严重心脏病,疲乏;手足综合征;腹泻;高血压;肝酶升高,华法林;西柚汁,低脂餐时服用,D,正常剂量,肝功能损害时谨慎,mg,口服,QD,2025-01-15,通用肿瘤数据库,已验证,基于通用肿瘤知识扩充
IT001,CA946414-94-4,0003-3801-11,00003380111001,L01XC17,1374640,A2F83W92SS,CHEMBL1202301,57394,DB09037,D10316,pembrolizumab,Pembrolizumab,PEM,帕博利珠单抗,可瑞达,默沙东,国药准字J20180006,16,PD-1单克隆抗体,100mg,200mg,9每3周1次,6静脉注射,黑色素瘤;肺癌;头颈癌;霍奇金淋巴瘤,严重自身免疫病;器官移植史,免疫相关不良反应;疲乏;皮疹;甲状腺功能异常,免疫抑制剂;糖皮质激素,输注前预处理,C,正常剂量,肝功能损害时谨慎,mg,静脉注射,Q3W,2025-01-15,通用肿瘤数据库,已验证,基于通用肿瘤知识扩充
IT002,CA1374853-91-4,0003-3802-11,00003380211001,L01XC16,1374853,7G6DM6Y8S7,CHEMBL1202302,148124,DB11714,D10481,nivolumab,Nivolumab,NIV,纳武利尤单抗,欧狄沃,百时美施贵宝,国药准字J20180026,16,PD-1单克隆抗体,40mg;100mg,240mg,8每2周1次,6静脉注射,黑色素瘤;肺癌;肾癌;头颈癌,严重自身免疫病;器官移植史,免疫相关不良反应;疲乏;皮疹;腹泻,免疫抑制剂;糖皮质激素,输注前监测甲状腺功能,C,正常剂量,肝功能损害时谨慎,mg,静脉注射,Q2W,2025-01-15,通用肿瘤数据库,已验证,基于通用肿瘤知识扩充
IT003,CA1537032-82-8,0078-0466-51,00078046651001,L01XC32,1537032,4Z6ST230YM,CHEMBL1202303,148124,DB11714,D11054,atezolizumab,Atezolizumab,ATE,阿替利珠单抗,泰圣奇,罗氏,国药准字J20190009,16,PD-L1单克隆抗体,840mg;1200mg,1200mg,9每3周1次,6静脉注射,肺癌;三阴性乳腺癌;尿路上皮癌,严重自身免疫病;活动性自身免疫病,免疫相关不良反应;疲乏;恶心;食欲减退,免疫抑制剂;糖皮质激素,输注期间监测,C,正常剂量,肝功能损害时谨慎,mg,静脉注射,Q3W,2025-01-15,通用肿瘤数据库,已验证,基于通用肿瘤知识扩充
IT004,CA1537032-82-8,0003-3803-11,00003380311001,L01XC33,1537033,A2F83W92SS,CHEMBL1202304,148124,DB11714,D11055,durvalumab,Durvalumab,DUR,度伐利尤单抗,英飞凡,阿斯利康,国药准字J20190010,16,PD-L1单克隆抗体,120mg;500mg,10mg/kg,8每2周1次,6静脉注射,肺癌;尿路上皮癌,严重自身免疫病;活动性感染,免疫相关不良反应;疲乏;皮疹;咳嗽,免疫抑制剂;糖皮质激素,输注前监测肺功能,C,正常剂量,肝功能损害时谨慎,mg,静脉注射,Q2W,2025-01-15,通用肿瘤数据库,已验证,基于通用肿瘤知识扩充
IT005,CA1374640-70-6,0003-3804-11,00003380411001,L01XC18,1374641,43B2M34G2V,CHEMBL1202305,148124,DB11714,D10317,ipilimumab,Ipilimumab,IPI,伊匹木单抗,易普利姆玛,百时美施贵宝,国药准字J20190008,16,CTLA-4单克隆抗体,50mg;200mg,3mg/kg,10每12周1次,6静脉注射,黑色素瘤,严重自身免疫病;炎症性肠病,免疫相关不良反应;腹泻;皮疹;肝炎,糖皮质激素;免疫抑制剂,严密监测免疫相关不良反应,C,正常剂量,肝功能损害时谨慎,mg,静脉注射,Q12W,2025-01-15,通用肿瘤数据库,已验证,基于通用肿瘤知识扩充
